| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | 
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Total Revenue | 39.89M | 39.77M | 25.87M | 2.67M | 6.01M | 12.44M | 
| Gross Profit | 1.09M | 968.93K | 843.62K | 60.17K | 551.40K | 1.78M | 
| EBITDA | -3.33M | -3.39M | -5.85M | -2.11M | -3.56M | -19.71M | 
| Net Income | -3.42M | -3.48M | -6.28M | -3.03M | -6.18M | -20.12M | 
| Balance Sheet | ||||||
| Total Assets | 8.30M | 8.30M | 4.37M | 6.37M | 10.08M | 17.34M | 
| Cash, Cash Equivalents and Short-Term Investments | 1.72M | 1.72M | 2.03M | 1.55M | 3.04M | 4.26M | 
| Total Debt | 1.16M | 1.16M | 2.19M | 0.00 | 520.24K | 3.06M | 
| Total Liabilities | 5.64M | 5.64M | 3.80M | 1.26M | 5.98M | 11.98M | 
| Stockholders Equity | 2.55M | 2.55M | 524.74K | 5.11M | 4.18M | 5.39M | 
| Cash Flow | ||||||
| Free Cash Flow | -4.26M | -4.26M | -2.84M | -3.46M | -5.35M | -10.48M | 
| Operating Cash Flow | -4.26M | -4.26M | -2.66M | -3.46M | -4.64M | -7.99M | 
| Investing Cash Flow | -38.83K | -38.83K | -318.20K | -192.52K | 589.87K | -2.59M | 
| Financing Cash Flow | 3.93M | 3.93M | 3.58M | 2.00M | 2.59M | 6.59M | 
Aumake Limited has entered into a non-binding Cooperation Framework Agreement with Sinomach Hainan Development Co., Ltd., a subsidiary of China National Machinery Industry Corporation. This partnership marks Sinomach’s first commercial engagement in Australia and aims to develop a large-scale Premium Hay Supply Chain Project. The project will initially cover 3,000 hectares, with plans to expand to 20,000 hectares, targeting an annual production capacity of 300,000 tonnes. Aumake will manage the Australian operations, while Sinomach will provide technology, infrastructure, and capital support. This collaboration aligns with China’s broader strategy to strengthen international agricultural supply chains and offers Aumake access to Sinomach’s extensive resources and market demand.
Aumake Limited has launched Bio-Basic Ergothioneine, marking the first brand under its new capital-light incubation model. This strategy aims to develop high-margin health and wellness brands with minimal capital investment, allowing Aumake to retain acquisition rights for successful brands. The launch, supported by a partnership with Mijing Media, combines online and offline distribution channels, enhancing Aumake’s market positioning in China’s premium health market. The initiative demonstrates the viability of Aumake’s model and sets the stage for future brand developments.
AuMake Limited announced a late lodgement of Appendix 3Z related to Ms. Hai Yun Chen due to an administrative oversight. The company assured stakeholders that this is an isolated incident and affirmed their commitment to compliance with ASX Listing Rules, indicating no significant impact on their operations or industry positioning.
Aumake Limited has announced a leadership transition following the completion of a strategic review, which has provided a roadmap for focusing on high-margin growth opportunities and capital-light distribution models. The resignation of Executive Director Hai Yun Chen is part of the company’s strategy to enhance decision-making and operational focus, with aggressive cost-cutting measures underway to improve cash flow and long-term profitability. This transition marks a significant step in Aumake’s efforts to streamline operations and prioritize margin expansion, positioning the company for sustainable growth and enhanced shareholder value.
AuMake Limited has released its corporate governance statement for the financial year ending June 30, 2025, in compliance with ASX Listing Rules. The statement, available on the company’s website, outlines the extent to which AuMake has adhered to the ASX Corporate Governance Council’s recommendations. This disclosure is crucial for stakeholders as it provides transparency regarding the company’s governance practices and any deviations from recommended practices, which could impact investor confidence and the company’s market positioning.